Literature DB >> 21849415

Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy.

Holger Kraiczi1, Anna Hansson, Roland Perfekt.   

Abstract

INTRODUCTION: As the efficacy of nicotine replacement therapy might be improved by faster systemic nicotine uptake, a new nicotine mouth spray has been developed. The current study was performed to evaluate the single-dose pharmacokinetics of nicotine at 3 doses of the mouth spray and to compare the speed of nicotine uptake from the spray versus nicotine lozenge and gum.
METHODS: In a randomized crossover study, 45 healthy adult smokers received single doses of nicotine mouth spray 1, 2, and 4 mg, nicotine lozenge 4 mg, and nicotine gum 4 mg on separate occasions. Blood samples were collected for 12 hr to determine pharmacokinetic variables.
RESULTS: Mean plasma nicotine concentrations during the first 10 min, measured using area under the curve (AUC(10 min)), were 3 times as high with spray 4 mg as with lozenge or gum. The AUC(10 min) with 2 and 1 mg doses of spray, respectively, was twice and 1.5 times as high as the AUC(10 min) with lozenge or gum. The maximum baseline-corrected plasma nicotine concentration (cC(max)) with 4 mg spray exceeded that for lozenge and gum by 34% and 20%; the median time to reach C(max) was 10-12.5 min for the 3 doses of spray, 45 min for lozenge, and 30 min for gum. The mean baseline-corrected area under the plasma nicotine concentration-versus-time curve (cAUC(∞)) with 4 mg spray was 15% higher than that with gum but did not differ significantly from that with lozenge.
CONCLUSION: Nicotine delivered via the mouth spray is absorbed considerably faster than nicotine given via gum or lozenge.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849415     DOI: 10.1093/ntr/ntr139

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  10 in total

1.  Characterization of the adverse effects of nicotine on placental development: in vivo and in vitro studies.

Authors:  A C Holloway; A Salomon; M J Soares; V Garnier; S Raha; F Sergent; C J Nicholson; J J Feige; M Benharouga; N Alfaidy
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-24       Impact factor: 4.310

2.  Comparison of nicotine oral soluble film and nicotine lozenge on efficacy in relief of smoking cue-provoked acute craving after a single dose of treatment in low dependence smokers.

Authors:  Daniel Du; Mitchell Nides; James Borders; Alex Selmani; William Waverczak
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

3.  The effect of smoking cessation pharmacotherapies on pancreatic beta cell function.

Authors:  Amanda K Woynillowicz; Sandeep Raha; Catherine J Nicholson; Alison C Holloway
Journal:  Toxicol Appl Pharmacol       Date:  2012-08-27       Impact factor: 4.219

4.  Effect of nicotine lozenge use prior to smoking cue presentation on craving and withdrawal symptom severity.

Authors:  Michael Kotlyar; Rachel I Vogel; Sheena R Dufresne; Anne M Mills; John P Vuchetich
Journal:  Drug Alcohol Depend       Date:  2019-11-02       Impact factor: 4.492

Review 5.  Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems.

Authors:  Lion Shahab; Leonie S Brose; Robert West
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

6.  Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial.

Authors:  Anna Hansson; Peter Hajek; Roland Perfekt; Holger Kraiczi
Journal:  BMJ Open       Date:  2012-09-26       Impact factor: 2.692

7.  Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.

Authors:  Philip Tønnesen; Hans Lauri; Roland Perfekt; Karl Mann; Anil Batra
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

8.  Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System.

Authors:  Axel Teichert; Patrick Brossard; Loyse Felber Medlin; Larissa Sandalic; Mikael Franzon; Chris Wynne; Murray Laugesen; Frank Lüdicke
Journal:  Nicotine Tob Res       Date:  2018-03-06       Impact factor: 4.244

9.  Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration.

Authors:  Per O Olsson Gisleskog; Juan José Perez Ruixo; Åke Westin; Anna C Hansson; Paul A Soons
Journal:  Clin Pharmacokinet       Date:  2020-12-23       Impact factor: 6.447

10.  A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products.

Authors:  David Azzopardi; James Ebajemito; Michael McEwan; Oscar M Camacho; Jesse Thissen; George Hardie; Richard Voisine; Gavin Mullard; Zvi Cohen; James Murphy
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.